There was a significant difference in the survival distribution across all score groups in the original (p < 0.001; panel A) and TTV-based (p < 0.001; panel B) CLIP scoring system. patients with higher serum -fetoprotein (AFP) levels or with vascular invasion. The Child-Turcotte-Pugh score, performance status, vascular invasion, AFP level and TTV were significant impartial prognostic predictors in the Cox proportional hazards model. After adjustment, patients with TTV 50-200 cm3(relative risk [RR]: 1.74, p = 0.009), 200-500 cm3(RR: 2.15, p = 0.006) and >500 cm3(RR: 3.92, p < 0.001) had a significantly increased mortality risk in comparison to patients with TTV <10 cm3. == 5,15-Diacetyl-3-benzoyllathyrol Conclusions == TTV is usually a feasible prognostic predictor across a wide gradient and can be used to predict the mortality risk of HCC. Selecting appropriate cutoffs of TTV may help refine the design of cancer staging system and treatment planning. Future clinical trials of HCC may include this parameter for mortality risk stratification. == Background == Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world [1,2]. The prognosis for patients with HCC is usually often very poor. Among the reported prognostic predictors for HCC, the size and number of tumor nodule, which represent tumor burden, are frequently associated with the aggressiveness of HCC and are of primary importance in determining the 5,15-Diacetyl-3-benzoyllathyrol clinical outcome of these patients [3-6]. The size and number of tumor or the extent of tumor involvement have also been included into the staging systems for HCC [7]. In addition, the selection of treatment modality for HCC is also highly dependent on the number and size of tumor nodule. For instance, the Milan criteria are 5,15-Diacetyl-3-benzoyllathyrol widely accepted standards for HCC patients undergoing liver transplantation [8-10], whereas patients undergoing partial hepatectomy usually have a maximal tumor number 5,15-Diacetyl-3-benzoyllathyrol of two or three. For patients undergoing percutaneous ethanol or acetic acid injection or radiofrequency ablation, the largest size of tumor is usually set at 3 cm and the number of tumor nodule usually does not exceed 3 [11,12]. However, for patients beyond these criteria, the treatment selection may widely vary and the prognostic prediction may become quite difficult. A major reason for this uncertainty and heterogeneity in cancer therapy is that a single determinant representing tumor burden has not yet been specifically defined. For example, the prognosis for a patient with a single 6 cm-sized HCC may not be the same for a patient with 3 nodules with a tumor diameter of 4, 3 and 2 cm for each nodule. As such, it is difficult to assess the prognosis for patients with a variable number and size of tumor nodules, and this difficulty may make the application of the currently used prognostic models for HCC less practical and clinically feasible. The concept of using total tumor volume (TTV) to represent tumor burden has been proposed by impartial study groups [13,14]. By combining the factor of size and number of tumor nodule, we aimed to define the tumor burden by using TTV in assessing the long-term outcome of patients with HCC. In this study, we have investigated the feasibility of TTV, its association with other clinical parameters and its predictive accuracy in patients with Mouse monoclonal to CTNNB1 HCC undergoing locoregional therapy. == Methods == == 5,15-Diacetyl-3-benzoyllathyrol Patients and diagnosis == Patients with newly diagnosed HCC in our hospital were evaluated since April 2002. The clinical parameters in these patients were prospectively assessed and recorded. The diagnosis of HCC was histologically verified by needle biopsy, or based on the findings of common radiological features in at least two image examinations including ultrasound, contrast-enhanced dynamic computed tomography (CT), magnetic resonance imaging and hepatic angiography, or by a.